Pharmala Biotech Holdings Inc. MDXXF
OTC PK
| 05/31/2026 | 02/28/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 82.96% | 38.07% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 82.96% | 38.07% | |||
| Cost of Revenue | 680.37% | -34.80% | |||
| Gross Profit | 31.13% | 52.89% | |||
| SG&A Expenses | 50.34% | 16.29% | |||
| Depreciation & Amortization | 1.39% | 1.41% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 69.27% | 10.92% | |||
| Operating Income | -56.54% | 6.24% | |||
| Income Before Tax | -48.07% | 16.29% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -48.07% | 16.29% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -48.07% | 16.29% | |||
| EBIT | -56.54% | 6.24% | |||
| EBITDA | -59.14% | 6.60% | |||
| EPS Basic | -43.48% | 14.81% | |||
| Normalized Basic EPS | -40.00% | -7.14% | |||
| EPS Diluted | -43.48% | 14.81% | |||
| Normalized Diluted EPS | -40.00% | -7.14% | |||
| Average Basic Shares Outstanding | 0.14% | 0.81% | |||
| Average Diluted Shares Outstanding | 0.14% | 0.81% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||